SAN DIEGO, April 2, 2014 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, has been invited to present at the 13th
Annual Needham Healthcare Conference, which will be held in
New York April 8-9, 2014.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting at 8:40 am, April
9th. The conference is being held at The
Westin New York Grand Central Hotel, New
York, NY.
Needham's Healthcare Conference focuses on connecting leading
emerging life science companies and institutional investors.
This year, senior management teams from approximately 120 companies
in the biotechnology, specialty pharmaceutical, medical technology
and diagnostic sectors are scheduled to present. The life
sciences sector is enjoying its fourth straight year of
outperforming the broader market. One-on-one meetings with
companies will be available for qualified institutional investors
and venture capital firms.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
Company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. In addition to numerous scientific publications, the
Company's technology has been featured in The Wall Street Journal,
Time Magazine, The Economist, and numerous others. Organovo is
changing the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
prospectus supplement filed with the SEC on November 27, 2013 and our transition report on
Form 10-KT filed with the SEC on May 24,
2013 as well as our other filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that
they were made. These cautionary statements should be considered
with any written or oral forward-looking statements that we may
issue in the future. Except as required by applicable law,
including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.